12 peptide melanoma vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2000 (NCT00938223)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 12 melanoma peptides restricted by class i mhc
- 12 peptide melanoma vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00071981 | Phase 2 | Mar 1, 2005 | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), University of Virginia |
| NCT00938223 | Phase 2 | Aug 1, 2000 | University of Virginia |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Virginia | Academic/Hospital | 2 | 1 | 1 | 2000 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2005 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2005 |
3 organizations
Page 1 / 1